Abstract:

Objective　To investigate the mid- and long- term efficacy and safety of percutaneous balloon compression (PBC) in the treatment of drug-resistant primary trigeminal neuralgia. Methods　The clinical data of 10 patients with drug-resistant primary trigeminal neuralgia who were treated with PBC in Department of Pain Medicine, The First People's Hospital of Kashgar from May to November 2019 were retrospectively analyzed, including 5 males and 5 females, with an average age of 66.8 years old. The patients were followed up every 6 months after discharge. The Visual Analogue Scale (VAS) and Numerical Rating Scale (NRS) were used to evaluate the patients' pain degree, and the complications and recurrence of primary trigeminal neuralgia were recorded. The curative effect was judged at the last follow-up. Friedman M rank sum test and q test were used. Results　All the 10 PBC surgeries had a smooth operation. At follow-up of 6 months after discharge, 1 patient was found to have facial hypoesthesia, and her prognosis was good without special treatment. During the follow-up, there were no recurrence and no complications such as chewing weakness, perioral herpes, keratitis, or diplopia. The effective rate was 100.0% (10/10) at the last follow-up of 3 years after discharge. The patients' VAS and NRS scores were decreased immediately after surgery and 6 months, 1 year, 1.5 years, 2 years, 2.5 years, and 3 years after discharge compared with those before surgery, with statistically significant differences (all P<0.05). Conclusion　PBC is safe and effective in the treatment of drug-resistant primary trigeminal neuralgia in about 3 years.

Key words:

Primary trigeminal neuralgia, Percutaneous balloon compression, Curative effect, Safety

摘要：

目的　探讨经皮穿刺三叉神经半月节微球囊压迫术（PBC）治疗药物难治性原发性三叉神经痛患者的中远期疗效和安全性。方法　回顾性研究2019年5月至11月喀什地区第一人民医院疼痛科采用PBC治疗的10例药物难治性原发性三叉神经痛患者（男5例、女5例，平均年龄66.8岁）的临床资料，患者出院后每6个月随访1次，采用视觉模拟评分法（VAS）、数字评价量表（NRS）评估患者的疼痛程度，记录患者的并发症和原发性三叉神经痛复发情况。末次随访时判断患者的疗效。采用Friedman M秩和检验、q检验。结果　10例PBC手术均获成功，出院后6个月随访时发现1例患者面部感觉减退，未予特殊处理，预后良好。随访过程中无复发患者，无咬肌无力、口周疱疹和角膜炎、复视等并发症发生。出院后3年末次随访时患者治疗有效率为100.0%（10/10）。患者术后即刻及出院后6个月、1年、1.5年、2年、2.5年、3年随访时VAS、NRS评分均低于术前，差异均有统计学意义（均P<0.05）。结论　PBC治疗药物难治性原发性三叉神经痛患者3年内安全、有效。

关键词:

原发性三叉神经痛, 经皮穿刺微球囊压迫术, 疗效, 安全性